HMGN1 and melanoma: Similarly, pioneering in melanoma is the interest in the development of a new “alarmin‐based” vaccine, biotherapeutic, and phytotherapeutic strategies exploiting the immunoinductive, antiproliferative, and the cell‐killing potential that has emerged for HMGN1, hBD‐1, hBD‐2, and plant‐derived defensins.